Search results for "Prostaglandins F"

showing 10 items of 12 documents

The effects of prostaglandin F2α in the human eye

1985

The ocular effects of 200 micrograms of topically applied prostaglandin F2 alpha were studied in 18 nonglaucomatous volunteers. A fall in intraocular pressure was seen in the prostaglandin-treated eyes when compared with the placebo-treated control eyes. The maximum intraocular pressure reduction was observed at the 7th h and hypotensive ocular effect persisted for 24 h. Prostaglandins did not produce any change in pupillary diameter or signs of intraocular inflammation visible by anterior segment biomicroscopy or iris fluorescein angiography. The drug caused side effects: conjunctival hyperemia was constant and many patients complained of ocular smarting and headache. It could be useful in…

AdultMaleIntraocular pressuregenetic structuresOcular hypertensionProstaglandinHyperemiaDinoprostEyePupilCellular and Molecular Neurosciencechemistry.chemical_compoundHumansMedicineIris (anatomy)VolunteerIntraocular PressureAgedmedicine.diagnostic_testbusiness.industryProstaglandins FHeadacheMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesSensory SystemsOphthalmologymedicine.anatomical_structurechemistryAnesthesiaFemaleHuman eyesense organsbusinessConjunctivaGraefe's Archive for Clinical and Experimental Ophthalmology
researchProduct

Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension.

2005

Background: C-reactive protein (CRP) predicts cardiovascular outcome. Oxidative stress is considered to be involved in endothelial alteration. We hypothesized that in essential hypertension (EH), oxidative stress, as measured by 8-iso-prostaglandin-F2 alfa (8-iso-PGF2alfa), should be associated with increased CRP and endothelial activation, as evaluated by soluble intercellular adhesion molecule–1 (ICAM-1) and vascular adhesion molecule–1 (VCAM-1) plasma levels. Methods: In 83 subjects with mild EH and in 50 healthy control subjects we measured, in basal conditions, plasma levels of hs-CRP, 8-iso-PGF2 alfa, ICAM-1 and VCAM-1, and tumor necrosis factor–alfa (TNF-alfa). Results: Subjects with…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaEndotheliumVascular Cell Adhesion Molecule-1Inflammationmedicine.disease_causeEssential hypertensionEndothelial activationInternal medicineInternal MedicinemedicineHumansEndothelial dysfunctionSettore MED/14 - NefrologiabiologyTumor Necrosis Factor-alphabusiness.industryProstaglandins FC-reactive proteinC-reactive protein oxidative stress hypertension atherogenesis endothelial dysfunctionMiddle AgedIntercellular Adhesion Molecule-1medicine.diseaseOxidative StressC-Reactive ProteinEndocrinologymedicine.anatomical_structureCase-Control StudiesHypertensionbiology.proteinRegression AnalysisFemaleTumor necrosis factor alphaEndothelium Vascularmedicine.symptombusinessOxidative stress
researchProduct

Dietary fish protein lowers blood pressure and alters tissue polyunsaturated fatty acid composition in spontaneously hypertensive rats.

2003

Abstract Objectives To investigate the effect of two types of dietary protein on blood pressure, liver fatty acid desaturation and composition, and urine 6-keto-prostaglandin-F (PGF1α) level, the metabolite of prostacyclin. Methods 5-wk-old spontaneously hypertensive rats were fed 20% casein or purified fish protein. The fat source was 5% ISIO oil, which contains 47.9% (ω-6) and 1.7% (ω-3) total polyunsaturated fatty acids. After 2 mo on the diet, systolic blood pressure was reduced with fish protein compared with casein (189.8 ± 10.5 versus 220.7 ± 8.7). Results Excretion of 6-keto-PGF1α in urine was negatively correlated with blood pressure. Liver cholesterol and phospholipid concentratio…

Fatty Acid DesaturasesFish ProteinsMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMetabolitePhospholipidBlood PressureUrine6-Ketoprostaglandin F1 alphaBiologyExcretionchemistry.chemical_compoundDietary Fats UnsaturatedInternal medicineCaseinRats Inbred SHRmedicineAnimalsAntihypertensive Agentschemistry.chemical_classificationNutrition and DieteticsBody WeightProstaglandins FCaseinsLipid metabolismOrgan SizeLipid MetabolismLipidsRatsBlood pressureEndocrinologychemistryLiverHypertensionFatty Acids UnsaturatedMicrosomes LiverDietary ProteinsPolyunsaturated fatty acidNutrition (Burbank, Los Angeles County, Calif.)
researchProduct

The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications.

2002

Adjunctive therapy for the management of glaucoma is commonly used. Unfixed combinations of the prostaglandin analog latanoprost and other glaucoma medications have been demonstrated to effectively lower intraocular pressure (IOP). The range of reported additional reductions in IOP compared to a monotherapy baseline are as follows: latanoprost-timolol (13-37%), latanoprost-pilocarpine 2% (7-14%), latanoprost and carbonic anhydrase inhibitors (15-24.1%), and latanoprost and dipivefrin (15-28%). There is a fixed combination of latanoprost (0.005%) and timolol (0.5%) that has been investigated in Phase III trials in Europe and the United States. In these trials, it was noted that the efficacy …

Intraocular pressureMydriaticsgenetic structuresCombination therapymedicine.medical_treatmentAdrenergic beta-AntagonistsTimololGlaucomachemistry.chemical_compoundMedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureChemotherapyDipivefrinbusiness.industryGlaucomamedicine.diseaseeye diseasesOphthalmologyProstaglandin analogchemistryAnesthesiaProstaglandins F SyntheticLatanoprostDrug Therapy CombinationOcular Hypertensionsense organsOphthalmic SolutionsSafetybusinessmedicine.drugSurvey of ophthalmology
researchProduct

Update on topical carbonic anhydrase inhibitors

2001

Topical carbonic anhydrase inhibitors are a novel addition to the armamentarium of medical glaucoma treatment; dorzolamide has been available since 1995 and brinzolamide since 1998. They lower intraocular pressure by inhibiting carbonic anhydrase, a key enzyme for aqueous humor formation. Intraocular pressure-lowering activity of the substances appears to be the same and is similar to that of most other agents, but it does not reach the activity of the unselective beta-blocker timolol or the prostaglandin latanoprost. On concomitant treatment, additivity is reached with all other topical agents. A possible improvement of blood flow may offer an additional benefit, but its significance for t…

Intraocular pressuregenetic structuresBrinzolamideThiazinesGlaucomaTimololThiophenesPharmacologyEyeAqueous Humorchemistry.chemical_compoundDorzolamideCarbonic anhydrasemedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureCarbonic Anhydraseschemistry.chemical_classificationSulfonamidesDose-Response Relationship Drugbiologybusiness.industryGlaucomaGeneral Medicinemedicine.diseaseeye diseasesOphthalmologyEnzymechemistryProstaglandins F Syntheticbiology.proteinLatanoprostsense organsOphthalmic SolutionsbusinessBlood Flow Velocitymedicine.drugCurrent Opinion in Ophthalmology
researchProduct

Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.

2014

Lowering intraocular pressure (IOP) is at present the only therapeutic approach to the treatment of glaucoma proven to be successful. The choice of therapy must take into account efficacy, tolerability, safety, quality of life, adherence and cost. Monotherapy fails to achieve a satisfactory IOP reduction in 40 - 75% of glaucoma patients after2 years of therapy. So far, three prostaglandin/timolol maleate 0.5% fixed combinations (FCs) are available.This review provides a background on the tafluprost-timolol FC (TTFC, Santen Oy) and its individual compounds. It summarizes the data on efficacy and safety, including comparative data with prostaglandin/timolol FCs already available.Tafluprost is…

Intraocular pressuregenetic structuresOpen angle glaucomaDrug-Related Side Effects and Adverse ReactionsOcular hypertensionTimololGlaucomamedicineHumansPharmacology (medical)Antihypertensive AgentsPharmacologybusiness.industryProstaglandins FTafluprostGlaucomaGeneral Medicinemedicine.diseaseeye diseasesDrug CombinationsProstaglandin analogTolerabilityAnesthesiaTimololDrug Evaluationlipids (amino acids peptides and proteins)Ocular Hypertensionsense organsbusinessGlaucoma Open-Anglemedicine.drugExpert opinion on pharmacotherapy
researchProduct

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.

2019

ObjectivesBimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma (OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost–timolol to PF tafluprost–timolol eye drops.DesignThis was a 12-week, open-label, phase IV study.SettingSixteen centres in Finland, Germany, Italy and the UK.ParticipantsPa…

MaleIntraocular pressuregenetic structuresOcular hypertensionGlaucomaTimololBenzalkonium chloride0302 clinical medicine1506clinical pharmacology; clinical trials; glaucoma; intraocular pressure; medical ophthalmology; ocular surface; Medicine (all)Aged 80 and overintegumentary systemMedicine (all)General MedicineMiddle AgedIntention to Treat AnalysisDrug Combinations030220 oncology & carcinogenesisTimololFemaleGlaucoma Open-Anglemedicine.drug1718Adultmedicine.medical_specialtyDrug Administration Schedule03 medical and health sciencesOphthalmologymedicineHumansAntihypertensive AgentsIntraocular PressureAgedclinical trialsocular surfaceBimatoprostbusiness.industryResearchPreservatives PharmaceuticalProstaglandins FTafluprostmedicine.diseaseeye diseasesmedical ophthalmologyClinical trialOphthalmologyBimatoprostglaucoma030221 ophthalmology & optometryQuality of LifeOcular Hypertensionsense organsclinical pharmacologyOphthalmic SolutionsbusinessBMJ open
researchProduct

Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.

2010

. Purpose:  The purpose of this study was to investigate the tolerability and intraocular pressure (IOP) reducing effect of the first preservative-free prostaglandin tafluprost (Taflotan®) in patients exhibiting ocular surface side-effects during latanoprost (Xalatan®) treatment. Methods:  A total of 158 patients were enrolled in this open-label multicentre study. Eligible patients had to have at least two ocular symptoms, or one sign and one symptom, during treatment with latanoprost. At baseline, the patients were directly switched from latanoprost to preservative-free tafluprost for 12 weeks. The patients were queried for ocular symptoms, and ocular signs were assessed by using tear brea…

MaleIntraocular pressuregenetic structuresmedicine.medical_treatmentAdministration TopicalMucin 5ACmedicine.disease_causeExfoliation SyndromeConjunctival Diseaseschemistry.chemical_compoundSurveys and QuestionnairesMedicineLatanoprostAged 80 and overBlepharitisGeneral MedicineMiddle AgedTolerabilityPatient SatisfactionAnesthesiaProstaglandins F SyntheticLatanoprostFemalemedicine.symptomIrritationBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugAdultGonioscopyHyperemiaTonometry OcularHumansBlepharitisAntihypertensive AgentsIntraocular PressureAgedGlaucoma medicationbusiness.industryPreservatives PharmaceuticalProstaglandins FTafluprostHLA-DR Antigensmedicine.diseaseeye diseasesOphthalmoscopyOphthalmologychemistryQuality of LifeItchingOcular Hypertensionsense organsbusinessActa ophthalmologica
researchProduct

The effect of the pro-inflammatory cytokine tumor necrosis factor-alpha on human joint capsule myofibroblasts.

2009

Introduction Previous studies have shown that the number of myoblastically differentiated fibroblasts known as myofibroblasts (MFs) is significantly increased in stiff joint capsules, indicating their crucial role in the pathogenesis of post-traumatic joint stiffness. Although the mode of MFs' function has been well defined for different diseases associated with tissue fibrosis, the underlying mechanisms of their regulation in the pathogenesis of post-traumatic joint capsule contracture are largely unknown. Methods In this study, we examined the impact of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) on cellular functions of human joint capsule MFs. MFs were challenged w…

MalePathologymedicine.medical_treatmentFluorescent Antibody TechniqueGene ExpressionDinoprostExtracellular matrixPathogenesisElbow JointImmunology and AllergyCells CulturedReverse Transcriptase Polymerase Chain ReactionAntibodies MonoclonalMiddle AgedImmunohistochemistryExtracellular MatrixCytokinemedicine.anatomical_structureAntirheumatic AgentsCytokinesTumor necrosis factor alphaFemaleHip Jointmedicine.symptomInflammation MediatorsMyofibroblastmusculoskeletal diseasesmedicine.medical_specialtyanimal structuresContractureDiclofenacImmunologyBlotting Westernmacromolecular substancesBiologyCollagen Type IDinoprostoneRheumatologyJoint capsuleResearch articlemedicineHumansAgedCell ProliferationCyclooxygenase 2 InhibitorsTumor Necrosis Factor-alphaProstaglandins FFibroblastsActinsInfliximabCyclooxygenase 2Joint stiffnessContractureJoint CapsuleArthritis researchtherapy
researchProduct

Fine Structural Evaluation of the Iris After Unilateral Treatment With Latanoprost in Patients Undergoing Bilateral Trabeculectomy (The Mainz II Stud…

2003

Objective To investigate by masked electron microscopy whether 6 months of topical latanoprost caused pathological changes in the peripheral iris of patients with glaucoma. Methods Seventeen patients with bilateral primary open-angle glaucoma requiring trabeculectomy were recruited for this study. The iridectomy taken during surgery on the first eye served as a control. The second test eye was treated topically with latanoprost for 6 months before its trabeculectomy. Fourteen patients completed the treatment arm of the study, and 1 of these underwent marked color change. As a result, 31 iridectomy specimens were fixed, coded, and evaluated. Results The specimens were evaluated for evidence …

Malemedicine.medical_specialtygenetic structuresAdministration Topicalmedicine.medical_treatmentEye diseaseIrisGlaucomaTrabeculectomyMelanocyteExfoliation Syndromechemistry.chemical_compoundDouble-Blind MethodOphthalmologymedicineHumansTrabeculectomyIris (anatomy)LatanoprostAntihypertensive AgentsAgedMelaninsbusiness.industryEye dropMiddle Agedmedicine.diseaseeye diseasesOphthalmologymedicine.anatomical_structurechemistryIridectomyProstaglandins F SyntheticLatanoprostMelanocytesFemalesense organsbusinessGlaucoma Open-AngleArchives of Ophthalmology
researchProduct